
    
      Botulinum toxin Type A 300U has been discontinued from the study after regulatory approval of
      botulinum toxin Type A 200U. Patients remaining in the study who were allocated to receive
      botulinum toxin Type A 300U at treatment 2 (and had not yet received it) will receive
      botulinum toxin Type A 200U instead.
    
  